Biosimilar Information Wars: Draft Guidance Seeks To Clamp Down On Efforts To Hinder Uptake In The US

 
• By Derrick Gingery
  
Advertising
The US FDA said in draft guidance that accurate information comparing a biosimilar and its reference could be considered misleading if offered in the wrong context. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance